Heptares initiates expansion plan
This article was originally published in Scrip
Executive Summary
Heptares Therapeutics, the UK biotechnology company that managed to buck the trend and raise £21 million in a series A financing round earlier this year led by Clarus Ventures, has begun spending the money.